Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2021 | Benefits of T1 substaging for NMIBC

Christiaan De Jong, MD, Erasmus University Medical Center, Rotterdam, The Netherlands, gives an overview of the benefits of T1 substaging of patients with non-muscle invasive bladder cancer (NMIBC) to identify patients who are at a high risk of progression after Bacillus Calmette-Guérin (BCG) therapy, and to identify optimal candidates for BCG therapy. Dr De Jong comments on a risk stratification model developed by the European Association of Urology (EAU) and describes the known benefits of substaging, as well as highlighting the need for larger studies. Dr De Jong also talks on the findings of a study which analyzed genomic data from 700 patients with BCG-treated T1 high-grade bladder cancer. This interview took place at the virtual EAU Virtual Meeting 2021.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.